Daniel Bensen - Jul 19, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Operating Officer
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Jul 19, 2023
Transactions value $
-$63,250
Form type
4
Date filed
7/21/2023, 08:52 PM
Previous filing
Jul 17, 2023
Next filing
Aug 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $126 +207 +0.04% $0.61* 528K Jul 19, 2023 Direct
transaction TYRA Common Stock Sale -$3.33K -207 -0.04% $16.08 528K Jul 19, 2023 Direct F1
transaction TYRA Common Stock Options Exercise $2.38K +3.9K +0.74% $0.61* 532K Jul 21, 2023 Direct
transaction TYRA Common Stock Sale -$62.4K -3.9K -0.73% $16.01 528K Jul 21, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -207 -0.15% $0.00 137K Jul 19, 2023 Common Stock 207 $0.61 Direct F3
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -3.9K -2.84% $0.00 134K Jul 21, 2023 Common Stock 3.9K $0.61 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.07. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.